MEDIAN TECHNOLOGIES (EPA:ALMDT) | Finanzwire

Basculer en Français

9777	Companies
195686	Keywords
126721	Articles
104053	Press releases

Home
Companies
MEDIAN TECHNOLOGIES

PRESS RELEASE

published on 07/09/2025 at 17:45, 6 months 21 days ago

Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Median Technologies reports half-year liquidity contract details with TP ICAP. 60,808 shares and €58,893.66 cash as of June 30, 2025. 469 buy and 395 sell transactions in the first half of 2025

Liquidity Contract Transactions Shares TP ICAP Median Technologies
BRIEF

published on 05/16/2025 at 17:50, 8 months 14 days ago

Median Technologies Announces Voting Rights and Share Capital Details

Share Capital Voting Rights Treasury Shares AMF Regulations Median Technologies
PRESS RELEASE

published on 05/16/2025 at 17:45, 8 months 14 days ago

Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Median Technologies discloses total voting rights and shares as of April 30, 2025, in compliance with regulations. The French company utilizes AI for cancer diagnosis and treatment

Voting Rights Shares AI Median Technologies Cancer Diagnosis
BRIEF

published on 03/14/2025 at 17:50, 10 months 16 days ago

Median Technologies Maintains its Eligibility for the PEA-PME Scheme

PEA-PME Euronext Growth Tax Benefits Eligibility Median Technologies
BRIEF

published on 02/24/2025 at 17:50, 11 months 6 days ago

Median Technologies: Presentation of eyonis™ LCS at ECR 2025

Artificial Intelligence Median Technologies Lung Cancer Eyonis™ LCS ECR 2025
BRIEF

published on 01/31/2025 at 08:05, 11 months 30 days ago

Median Technologies unveils its 2024 financial results and its 2025 outlook

Financial Results FDA Approval Median Technologies Eyonis™ LCS Expansion 2025
PRESS RELEASE

published on 01/31/2025 at 08:00, 11 months 30 days ago

Inside Information / Other news releases
Median Technologies reports 2024 financial indicators and 2025 outlook, including eyonis™ LCS FDA clearance and iCRO revenue growth. Strategic milestones and new financing agreements drive towards 2025 goals

Financial Indicators Median Technologies Eyonis LCS 2025 Outlook ICRO Revenue Growth
BRIEF

published on 01/24/2025 at 08:05, 1 year ago

Median Technologies Secures Up to €47.5 Million for AI Lung Cancer Diagnostics

European Investment Bank Median Technologies AI Lung Cancer Diagnostics Eyonis™ EU And US Commercialization
PRESS RELEASE

published on 01/24/2025 at 08:00, 1 year ago

Inside Information / Other news releases
Median Technologies secures up to €47.5 million for eyonis™ AI lung cancer diagnostic regulatory filings & U.S./EU commercialization. New financing & operational enhancements drive profitability & extend cash runway into Q4, 2025

AI Commercialization Median Technologies Lung Cancer Diagnostic Eyonis
BRIEF

published on 11/26/2024 at 17:50, 1 year 2 months ago

Median Technologies Showcases AI Lung Cancer Diagnostic at RSNA 2024

Clinical Trials Eyonis™ LCS RSNA 2024 AI-powered Diagnostics Lung Cancer Screening

Accesswire

Published on 01/30/2026 at 14:00, 8 hours 2 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 13 hours 27 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 14 hours 2 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 19 hours 47 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 22 hours 2 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

EQS Group

Published on 01/30/2026 at 20:10, 1 hour 52 minutes ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 1 hour 52 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 1 hour 55 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 19:13, 2 hours 49 minutes ago

Total Voting Rights
Published on 01/30/2026 at 18:31, 3 hours 30 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 01/30/2026 at 17:45, 4 hours 17 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 14 hours 2 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 4 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 4 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 4 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE